Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – Containing at least one abnormal peptide link – e.g. – gamma...
Reexamination Certificate
2006-03-14
2006-03-14
Stucker, Jeffrey (Department: 1648)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
Containing at least one abnormal peptide link, e.g., gamma...
C424S451000, C424S463000, C424S474000, C424S477000, C424S278100
Reexamination Certificate
active
07012129
ABSTRACT:
Embodiments relate to the discovery that certain tripeptide amides and glycine amide can be used to inhibit viral infection, including human immunodeficiency virus (HIV) infection. More specifically, medicaments comprising said tripeptide amides and/or glycine amide and methods of using said compounds for the prevention and treatment of viral infection, such as HIV infection, are provided.
REFERENCES:
patent: 4215112 (1980-07-01), Goldstein et al.
patent: 4528133 (1985-07-01), Kasafirek et al.
patent: 4612337 (1986-09-01), Fox et al.
patent: 4658013 (1987-04-01), Morgan
patent: 4818540 (1989-04-01), Chinen et al.
patent: 4857538 (1989-08-01), Kashman et al.
patent: 4950647 (1990-08-01), Robins et al.
patent: 5336758 (1994-08-01), Berzofsky et al.
patent: 5346989 (1994-09-01), Vahlne et al.
patent: 5449752 (1995-09-01), Fujii et al.
patent: 5470951 (1995-11-01), Roberts
patent: 5478810 (1995-12-01), Stuber et al.
patent: 5571892 (1996-11-01), Fujii et al.
patent: 5607858 (1997-03-01), Stuber et al.
patent: 5627035 (1997-05-01), Vahlne et al.
patent: 5710128 (1998-01-01), Fujii et al.
patent: 5744368 (1998-04-01), Goldgaber et al.
patent: 5770620 (1998-06-01), Mjalli et al.
patent: 5776899 (1998-07-01), Matsumoto et al.
patent: 5817626 (1998-10-01), Findeis et al.
patent: 5830910 (1998-11-01), Mattson
patent: 5830994 (1998-11-01), D'Hinterland et al.
patent: 5843904 (1998-12-01), Bemis et al.
patent: 5843995 (1998-12-01), Rana et al.
patent: 5846714 (1998-12-01), Haskill et al.
patent: 5854204 (1998-12-01), Findeis et al.
patent: 5856122 (1999-01-01), Read et al.
patent: 5858979 (1999-01-01), Kakkar et al.
patent: 5872210 (1999-02-01), Medabalimi
patent: 5886025 (1999-03-01), Pinney
patent: 5932550 (1999-08-01), Kato et al.
patent: 6184210 (2001-02-01), Keanna et al.
patent: 6242416 (2001-06-01), Gilchrest et al.
patent: 6258932 (2001-07-01), Vahlne
patent: 6455670 (2002-09-01), van der Spoel et al.
patent: 2002/0091086 (2002-07-01), Vahlne
patent: 0 421 074 (1991-04-01), None
patent: 0 894 855 (1999-02-01), None
patent: 0 900 566 (1999-03-01), None
patent: 2 668 488 (1992-04-01), None
patent: 1063727 (1967-03-01), None
patent: WO 90/04390 (1990-05-01), None
patent: WO 92/20795 (1992-11-01), None
patent: WO 96/27386 (1996-09-01), None
patent: WO 96/28162 (1996-09-01), None
patent: WO 96/35714 (1996-11-01), None
patent: WO 98/09985 (1998-03-01), None
patent: WO 98/35062 (1998-08-01), None
patent: WO 99/09056 (1999-02-01), None
patent: WO 99/09985 (1999-03-01), None
patent: WO 00/09158 (2000-02-01), None
patent: WO 01/10456 (2001-02-01), None
patent: WO 01/10457 (2001-02-01), None
Bachem catalog, Bachem Bioscience Inc. 1993, pp. 263 and 632.
Abdel-Meguid et al., “An orally bioavailable HIV-1 protease inhibitor containing an imidazole-derived peptide bond replacement: Crystallographic and pharmacokinetic analysis,”Biochemistry, 33(39):11671-11677 (1994).
Allured et al., “Structure of exotoxin A of pseudomonas aeruginosa at 3.0- angstrom resolution,”Proc Natl Acad Sci USA, 83(5):1320-1324 (1986).
Armstrong et al., “A phase 1 study of chemically synthesized verotoxin (Shiga-like toxin) Pk-trisaccharide receptors attached to chromosorb for preventing hemolytic-uremic syndrome,”J. Infectious Diseases,J14 171:1042-1045 (1995).
Armstrong and Peppler, “Maintenance of biological activity of pertussis toxin radioiodinated while bound to fetuin-agarose,”Infection&Immunity, 55(5):1294-1299 (1987).
Ashkenazi et al., “Safety and antitumor activity of recombinant soluble Apo2 ligand,”J Clinical Investigation, 104(2):155-162 (1999).
Bai et al., “Characterization of the interaction of cryptophycin 1 with tubulin: binding in the vinca domain, competitive inhibition of dolastatin 10 binding, and an unusual aggregation reaction,”Cancer Research, 56:4398-4406 (1996).
Barger et al., “Tumor necrosis factors α and β protect neurons against amyloid β-peptide toxicity: Evidence for involvement of a κB-binding factor and attentuation of peroxide and Ca2+ accumulation,”Proc Natl Acad Sci USA, 92:9328-9332 (1995).
Brandhuber et al., “Mapping the enzymatic active site of pseudomonas aeruginosa exotoxin A,”Proteins, 3(3):146-154 (1988).
Choe et al., “The crystal structure of diphtheria toxin,”Nature, 357(6375):216-222 (1992).
Chothia and Janin, “Principles of protein-protein recognition,” Nature, 256(5520):705-708 (1975).
Conner et al., “Selective Proteasome Inhibition Attenuates Experimental Polyarthritis Via Inhibition of Nuclear Transcription Factor κB (NFκB) Activation,”Arthritis and Rheumatism, Abst. Suppl., 40(9), (1997).
Conner et al., “Proteasome Inhibition Attentuates Nitric Oxide Synthase Expression, VCAM-1 Transcription and the Development of Chronic Colitis,”Journal of Pharmacology and Exp Therapeutics, 282(3):1615-1622, 1997.
Durso et al., “The antimitotic tripeptide hemiasterlin,”Proc Am Assoc Cancer Res Annual Meeting, vol. 40, p. 286, Mar. 1999.
Erickson et al., “Design, activity, and 2.8 A crystal structure of a C2 symmetric inhibior complexed to HIV-1 protease,” Science, 249(4968):527-533 (1990).
Gamble et al., “Structure of the carboxyl-terminal dimerization domain of the HIV-1 capsid protein,”Science, 278:849-853 (1997).
Glenner et al., “Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein,”Biochem Biophys Res Commun, 120(3):885-890 (1984).
Grannelli-Piperno, et al., “Efficient Interaction of HIV-1 with Purified Dendritic Cells via multiple chemokine Coreceptors,”J Exp Med, 184:2433-2438 (1996).
Hall et al., “Substituted 4-hydroxyproline di- and tri-peptides as cytotoxic agents,”Amino Acids, 16(1):79-89 (1999).
Head et al., “Preparation of VT1 and VT2 hybrid toxins from their purified dissociated subunits,”J Biol Chem, 266(6):3617-3621 (1991).
Henderson et al., “Gag proteins of the highly replicative MN strain of human immunodeficiency virus type 1: postranslational modifications, proteolytic processing, and complete amino acid sequences,”Journal of Virology, 66(4):1856-1865 (1992).
Hewlett et al., “Induction of a novel morphological response in Chinese hamster ovary cells by pertussis toxin,” Infect. Immun., 40(3):1198-1203 (1983).
Hilbich et al., “Substitutions of hydrophobic amino acids reduce the amyloidogenicity of alzheimer's disease βA4 peptides,”J Mol Biol, 228:460-473 (1992).
Huang et al., “The role of DNA in the mechanism of NFκB dimer formation: crystal structures of the dimerization domains of the p50 and p65 subunits,” Structure, 5(11):1427-1436 (1997).
Hwang et al., “Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1,”Science, 253:71-74 (1991).
Ito et al., “Isolation and some properties of A and B subunits of Vero toxin 2 and in vitro formation of hybrid toxins between subunits of Vero toxin 1 and Vero toxin 2 fromEscherichia coliO157:H7,”Microb Pathog, 5(3):189-195 (1988).
Jarret and Lansbury, “Seeding ‘One-dimensional crystallization’ of amyloid: a pathogenic mechanism in alzheimer's disease and scrapie?”Cell, 73:1055-1058 (1993).
Kowalski et al., “Functional regions of the envelope glycoprotein of human immunodeficiency virus type I,”Science, 237:1351-1355 (1987).
Lassila et al., “A Role for Lys-His-Gly-NH2 in Avian and Murine B Cell Development,”Cell. Immun., 122:319-328, (1989).
Latimer et al., “The N-terminal domain of IκBα Masks the nuclear localization signal(s) of p50 and c-Rel homodimers,” Mol. Cell Biol., 18(5):2640 (1998).
LeVine, “Thioflavine T interaction with synthetic Alzheimer's disease beta-amyloid peptides: detection of amyloid aggregation in solution,”Protein Sci
Goobar-Larsson Laura
Vahlne Anders
Knobbe Martens Olson & Bear LLP
Stucker Jeffrey
Tripep AB
LandOfFree
Antiviral composition comprising glycine amide does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antiviral composition comprising glycine amide, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antiviral composition comprising glycine amide will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3549399